Healthcare
Lineage Cell Therapeutics, Inc.(LCTX)
Live Price
Offline$1.21
-3.20% today
1Y Change
+17.76%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $380.00M
- Revenue Growth
- +53.2%
- EPS Growth
- -201.1%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Lineage Cell Therapeutics, Inc. (LCTX) is a Healthcare stock with a market cap of $380.00M and listed on AMEX. The stock last traded around $1.21 and up 17.8% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +53.2%, EPS growth of -201.1%, a dividend yield of 0.0%. What stands out right now is revenue +53.2%, EPS -201.1%, free cash flow +17.8% with operating margin -251.6% and ROIC -33.1%. Valuation already assumes a fairly strong business story at price/sales 26.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines LCTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+53.2% vs +7.6% peer median
Operating Margin
Below sector median
-251.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +53.2% and EPS is at -201.1%, with operating margin around -251.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -6.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | -3.8% | -9.8% | -7.5% |
2026 Mar 5, 2026 | +109.2% | +0.5% | -14.1% | -14.7% |
2025 Nov 6, 2025 | -550.0% | +1.7% | +4.0% | -0.6% |
Benchmark Edge
LCTX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LCTX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LCTX Max Drawdown
-39.29%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LCTX and SPY.
Company Overview
Lineage Cell Therapeutics, Inc.
New York Stock Exchange American
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
- Leadership
- Brian Culley
- IPO Date
- Mar 5, 1992
- Employees
- 70
- Street Address
- 2173 Salk Avenue
- Mailing
- Carlsbad, CA, 92008
- Region
- Carlsbad, CA, US
- Reporting Currency
- USD
- Investor Line
- 442 287 8990
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 26.1
- Price/Book
- 7.9
Growth
- Revenue
- +53.2%
- EPS
- -201.1%
- Free Cash Flow
- +17.8%
Profitability
- Gross Margin
- 94.2%
- Operating Margin
- -251.6%
- Net Margin
- -436.5%
- ROE
- -131.0%
- ROIC
- -33.1%
Balance Sheet
- Debt/Equity
- 0.05
- Current Ratio
- 5.20
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.